(QURE) uniQure N.V. SWOT Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(QURE) uniQure N.V. Complete Analysis Pack
Go Beyond the Preview—Access the Full Reference Sources
This uniQure N.V. SWOT Analysis gives a concise, company-specific breakdown of strengths, weaknesses, opportunities, and threats to support research, strategy, or investment decisions — and this page includes a real preview/sample of the actual content so you can judge style and substance. Purchase the full version to download the complete, ready-to-use analysis instantly.
Strengths
1 Phase III lead asset in hemophilia B
uniQure N.V.’s lead asset, etranacogene dezaparvovec (AMT-061), is the Phase III HOPE-B program in hemophilia B, with 54 patients in the pivotal trial. That gives uniQure its clearest near-term clinical and regulatory catalyst. Hemophilia B is a rare, high-need market, affecting about 1 in 25,000 male births, so a durable one-time gene therapy can command strong value.
7-program gene therapy pipeline
uniQure N.V. has 7 gene therapy programs in motion: AMT-061, AMT-130, AMT-060, AMT-210, AMT-260, AMT-161, and AMT-240. That gives the Company multiple shots on goal across different diseases and trial stages, so one setback is less likely to derail the whole pipeline. It also cuts reliance on any single readout, which matters in a high-risk, data-driven field.
4 CNS and neurodegeneration targets
uniQure N.V. has 4 CNS and neurodegeneration shots on goal: Huntington’s disease, Parkinson’s disease, temporal lobe epilepsy, ALS, and autosomal dominant Alzheimer’s disease. That widens its reach into huge unmet-need markets, including Parkinson’s affecting over 10 million people worldwide and Alzheimer’s over 55 million. This portfolio also reduces dependence on hemophilia and gives uniQure N.V. a more differentiated gene-therapy profile.
1998 founding with specialist focus
Founded in 1998, uniQure has 27 years of gene therapy focus, which supports deep know-how and process discipline. Its specialist model is narrower than a broad pharma mix, so capital and R&D stay concentrated on one platform, not split across many franchises.
- 1998 founding; 27 years' experience
- Focused gene-therapy platform
- Depth over portfolio breadth
Amsterdam headquarters and global footprint
uniQure is headquartered in Amsterdam, Netherlands, giving it a European base that helps attract international talent and connect with research networks across the EU. That footprint also supports cross-border development, which matters in rare disease, where trials and patient pools are often spread across countries. In 2025, the company kept a dual U.S.-Europe operating setup, which fits global commercialization plans.
- Amsterdam base supports EU talent access
- Cross-border model fits rare-disease trials
- Global setup helps commercialization reach
uniQure's 7-program pipeline and lead hemophilia B asset drive upside
uniQure N.V.’s strength is its lead hemophilia B asset, AMT-061, backed by the Phase III HOPE-B trial with 54 patients. Its 7-program pipeline lowers single-asset risk, and 4 CNS shots on goal broaden upside in large unmet-need markets. Founded in 1998, the Company brings 27 years of gene-therapy focus.
| Key strength | Data |
|---|---|
| Lead trial | 54 patients |
| Pipeline | 7 programs |
| Focus | 27 years |
| Founding | 1998 |
What is included in the product
Detailed Word Document
Outlines the strengths, weaknesses, opportunities, and threats shaping uniQure N.V.’s strategy.
Editable Excel File
Provides a clear uniQure N.V. SWOT snapshot to quickly identify risks and opportunities.
Reference Sources
Provides a concise, traceable bibliography of industry reports, regulatory filings, and peer-reviewed studies to validate uniQure N.V. assumptions and speed due diligence.
Weaknesses
Only 1 Phase III asset
uniQure N.V. has just 1 Phase III asset, HOPE-B, so most near-term upside rests on a single pivotal readout. That makes de-risked value thin versus larger biotech peers with multiple late-stage shots on goal. If HOPE-B misses, the pipeline loses its main late-stage catalyst and the stock’s success case gets hit hard.
Most programs remain early stage
uniQure N.V. still has 6 key programs stuck early: AMT-130, AMT-060, AMT-210, AMT-260 and AMT-161 are in Phase I/II, while AMT-240 is still preclinical. That means 5 of 6 assets remain in small, early human trials, where success rates are low and timelines are long. So meaningful revenue may still be years away, with high attrition risk at each step.
Heavy dependence on rare diseases
uniQure N.V. depends heavily on rare-disease programs, which limits its market size even when pricing is high. Its 2025 pipeline was still centered on ultra-small patient groups like Huntington’s disease and hemophilia B, so revenue can hinge on just a few readouts. That makes total sales uneven and caps upside unless several programs reach market.
Single lead indication concentration in hemophilia B
uniQure N.V. is heavily tied to hemophilia B: AMT-061 and AMT-060 both target the same disease, so one clinical or commercial setback can hit most of the pipeline story. Hemophilia B is rare, about 1 in 25,000 male births, but that also means a narrow market and limited backup if uptake slows. Hemgenix carries a list price near $3.5 million, so access and reimbursement risk matter a lot.
- One disease, high concentration risk
- Setback can hit most value
- Narrow market limits offset
No marketed multi-product platform described
uniQure still lacks a broad commercial product base. Its business is still driven mainly by development-stage assets, with only HEMGENIX approved, so cash generation and scale remain limited until more programs reach market.
- Single approved asset, not a platform
- Development risk still drives value
- Commercial cash flow remains narrow
That leaves uniQure dependent on clinical progress and financing, rather than diversified sales.
uniQure’s narrow pipeline leaves 2025 highly exposed
uniQure N.V. remains weak on concentration: 1 approved product, HEMGENIX, and a pipeline still dominated by early-stage assets. That leaves 2025 value tied to a few rare-disease readouts, with limited cash flow diversification and high clinical and financing risk.
| Weakness | Latest data |
|---|---|
| Approved assets | 1 product |
| Late-stage depth | 1 Phase III program |
| Early-stage pipeline | 6 key programs |
| Revenue base | Narrow, rare-disease led |
Preview the Actual Deliverable
uniQure N.V. Reference Sources
This is the actual uniQure N.V. SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality; the preview below is taken directly from the full report, and the complete, editable file is unlocked after payment.
Opportunities
HOPE-B may unlock hemophilia B commercialization
Positive HOPE-B data could support broad use of etranacogene dezaparvovec, a one-time gene therapy tested in the 54-patient HOPE-B study. A strong launch would be uniQure N.V.'s biggest near-term revenue driver and could accelerate uptake in a hemophilia B market where patients still need frequent factor IX prophylaxis. It would also validate uniQure N.V.'s gene therapy platform.
AMT-130 targets Huntington’s disease
AMT-130 is in Phase I/II for Huntington’s disease, a rare, fatal neurodegenerative disorder with about 30,000 people living with it in the U.S. and roughly 40,000 in Europe. There are no approved disease-modifying therapies, so even modest efficacy could change care. For uniQure N.V., clinical success could make AMT-130 one of its biggest long-term value drivers.
Pipeline spans 5 high-need CNS indications
uniQure’s CNS pipeline now spans five high-need indications: Huntington’s disease, Parkinson’s disease, temporal lobe epilepsy, ALS and Alzheimer’s disease. These are hard targets, but each sits in a very large unmet-need market, so even one win could meaningfully widen uniQure’s addressable market. In CNS, the prize is big because the patient pools are large and current treatment options remain limited.
Rare-disease pricing and orphan advantages
uniQure N.V. can benefit from orphan-drug economics: rare, severe genetic diseases support premium one-time gene-therapy pricing when clinical benefit is clear. The global gene therapy market was about $7.5 billion in 2025 and is expected to keep growing, while many approved orphan drugs still reach prices above $1 million per patient, showing how small populations can still create large value.
- Rare diseases support premium pricing
- Small pools can still drive revenue
- Strong efficacy can offset low prevalence
- Fits uniQure N.V.’s focused model
Partnership and licensing potential
uniQure N.V.’s AAV gene therapy platform, with 1 approved product and late-stage programs like AMT-130, is attractive to larger pharma groups that want fast entry into rare and neuro diseases. A partner deal can fund costly trials, share development risk across multiple assets, and extend global commercial reach without forcing uniQure to build every market on its own.
- Attracts big pharma seeking gene therapy access
- Shares trial cost and regulatory risk
- Expands reach beyond uniQure’s own footprint
uniQure’s Growth Catalysts: HOPE-B, Huntington’s, and a $7.5B Market
uniQure N.V.'s biggest upside is HOPE-B: if etranacogene dezaparvovec keeps showing durable bleed control, it can scale in hemophilia B, where patients still use frequent factor IX prophylaxis. AMT-130 also matters: Huntington’s has about 30,000 patients in the U.S. and 40,000 in Europe, with no approved disease-modifying therapy. Its five-program CNS pipeline and one approved product can also attract partners and support premium orphan pricing.
| Opportunity | Key data |
|---|---|
| HOPE-B launch | 54-patient study |
| Huntington’s | 30k U.S., 40k Europe |
| Gene therapy market | $7.5B in 2025 |
Threats
Phase III failure risk in HOPE-B
HOPE-B is uniQure’s pivotal Hemophilia B trial, and late-stage data risk is still a major threat. The study enrolled 54 patients, so any efficacy miss, safety signal, or delay could hit approval odds and the lead asset’s value. With uniQure reporting a $78.8 million net loss in Q1 2025, a setback could also tighten funding pressure.
Clinical attrition across 6 non-lead programs
AMT-130, AMT-060, AMT-210, AMT-260, AMT-161 and AMT-240 all carry binary clinical risk, and any setback can wipe out years of R&D spend. In biotech, only about 10% of drugs that enter Phase 1 reach approval, so early and preclinical programs fail often. With six non-lead shots on goal, uniQure could face several negative readouts before any new revenue.
Gene therapy safety and durability concerns
Gene therapy safety and durability remain key risks for uniQure N.V., because AAV-based programs can trigger immune reactions, liver stress, and other off-target effects, especially in systemic or CNS delivery. Regulators review these signals closely, and even one serious adverse event can delay trials, add monitoring costs, or slow approval. Long-term benefit is still hard to prove, so weak durability data can hurt physician trust and commercial uptake.
Competition in hemophilia and CNS gene therapy
uniQure faces heavy pressure in hemophilia and CNS gene therapy, where bigger rivals like CSL Behring, Pfizer, BioMarin and Roche have deeper capital, larger plants and stronger sales reach. Hemgenix launched at $3.5 million per dose and Roctavian at $2.9 million, showing how crowded and expensive this space is. That can squeeze uniQure’s share and weaken its deal terms.
- Large peers outspend on trials and scale
- Approved rivals already set price anchors
- Competition can cut market share and leverage
Reimbursement and regulatory pressure on one-time treatments
uniQure N.V. faces payer pushback because one-time gene therapies can carry multi-million-dollar upfront prices; Hemgenix launched at $3.5 million per patient. Insurers usually want long durability data and real-world proof before broad coverage, so any shift in FDA or payer stance can slow adoption even after approval.
- High upfront price can delay coverage
- Durability proof drives reimbursement
- Payer sentiment can slow uptake
uniQure’s HOPE-B gamble: one misstep could hit approval and cash
uniQure N.V.’s biggest threat is HOPE-B: 54 patients means one safety miss, efficacy miss, or delay could hurt approval odds and valuation. With a Q1 2025 net loss of $78.8 million, any setback also tightens cash pressure. AAV gene therapy still faces immune and durability risks, and bigger rivals can outspend it.
| Threat | Key data |
|---|---|
| HOPE-B risk | 54 patients; pivotal readout |
| Funding pressure | Q1 2025 net loss: $78.8M |
| Safety/durability | AAV immune and off-target risk |
| Competition | Deep-pocket rivals in hemophilia |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.